Clinical Microbiology and Antimicrobial Chemotherapy. 2003; 5(1):19-31
Moxifloxacin is a new broad spectrum 8-meth-oxiquinolon with high activity against both Gram(+) and Gram(–) microorganisms as well as against anaerobes and intracellular pathogens. It is also active against microorganisms that are resistant to other classes of antimicrobials, including penicillin and macrolide-resistant pneumococci and β-lactamase-producing Haemophilus influenzae. An excellent activity against the above mentioned pathogens and good pharmacokinetic profile allows to use moxifloxacin for monotherapy of respiratory tract infections. High clinical efficacy and safety of moxifloxacin has been demonstrated in treatment with sequential therapy of community-acquired pneumonia in the controlled clinical trials. The literature review of clinical trials on sequential (IV/PO) moxifloxacin therapy in patients with community-acquired pneumonia is presented in the article. An attempt to analyse the perspectives of further moxifloxacin usage is made.